A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus

What Was Tested

In this phase 3 trial, researchers set out to test Insulin Glargine.

Both drugs will be given by an injection under the skin.

Participants may continue to take oral antihyperglycemic medication (OAM) during the study, as prescribed by their personal physician.

It had two arms (groups): LY2605541 (experimental) and Insulin Glargine (active comparator).

The registry classes the interventions as drug.

Who Took Part

It was open to people of any sex aged from 20 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have T2DM (per World Health Organization \[WHO\] Classification of Diabetes) not treated with insulin. Have had diabetes for at least 1 year. Have been receiving at least 2 oral antihyperglycemic medications (OAMs) for at least 3 months prior to the study. Have body mass index (BMI) ≤40 kilogram/square meter (kg/m\^2).

The full record lists 6 inclusion and 12 exclusion criteria; among the exclusions: weight loss medications: are currently taking, or have taken within the 3 months preceding screening, prescription or over-the-counter medications to promote weight loss; severe hypoglycemia history: have had any episodes of severe hypoglycemia within 6 months prior to screening; diabetic ketoacidosis (dka) or hyperglycemic hyperosmolar nonketotic coma (hhnkc): have had 1 or more episodes of dka or hyperosmolar state/coma in the past 6 months.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Random assignment meant chance, not the researchers, decided who got Insulin Glargine and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Everyone knew when Insulin Glargine was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2015-02 with completion listed for 2015-11.

It ran at 10 sites in United States (10).

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Change from Baseline in Hemoglobin A1c (HbA1c) at 26 Week Endpoint (time frame: Baseline, 26 Weeks).

It also tracked 15 secondary outcomes, for example Rate of Total and Nocturnal Hypoglycemia Events, Fasting Serum Glucose (FSG) by Laboratory Measurements, 9 Point Self Monitored Blood Glucose, Change from Baseline in Body Weight at Week 26 Endpoint, Change from Baseline in HbA1c at 52 Week Endpoint and Time to Reach Steady-State.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Insulin Glargine in people.

It was withdrawn before enrolling anyone; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Insulin Glargine compound page, all human trials.